PT - JOURNAL ARTICLE AU - Vinall, Maria ED - Gabay, Cem TI - 24-Week Data from the Phase 4 ADACTA Trial DP - 2012 Sep 01 TA - MD Conference Express PG - 10--11 VI - 12 IP - 9 4099 - http://mdc.sagepub.com/content/12/9/10.short 4100 - http://mdc.sagepub.com/content/12/9/10.full AB - Results from the Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis trial [ADACTA; NCT01119859], suggest that tocilizumab monotherapy may be more effective than adalimumab monotherapy reducing the signs and symptoms of rheumatoid arthritis.